Shenzhen Majory Biotechnology Co., Ltd.
Clinical trials sponsored by Shenzhen Majory Biotechnology Co., Ltd., explained in plain language.
-
New hope for Hard-to-Treat breast cancer: experimental drug MR001 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MR001 in people with advanced triple-negative breast cancer (TNBC) that has worsened after previous treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow the disease. About 42 participants will recei…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 12:24 UTC
-
New combo therapy targets tough pancreatic cancer
Disease control Recruiting nowThis study tests a new drug called MR001 combined with standard chemotherapy for people with advanced pancreatic cancer that has worsened after initial treatment. The goal is to find a safe dose and see if the combination can shrink tumors or slow the disease. About 45 adults wit…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Majory Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC